COMMUNIQUÉS West-GlobeNewswire

-
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
07/07/2025 -
Skin Care and Laser Physicians of Beverly Hills Welcomes Double Board-Certified Dermatologist
07/07/2025 -
Corza Medical Announces the Launch of the Expanded Onatec Ophthalmic Suture Portfolio
07/07/2025 -
The American Society of Pain and Neuroscience (ASPN) Publishes Consensus Guidelines for the Use of 60-Day Peripheral Nerve Stimulation (PNS) Therapy, Highlighting Strong Clinical Applications for SPR® SPRINT® PNS
07/07/2025 -
Joybird’s Treehouse to Host Free Webinar on Academic Success for Underserved Students
07/07/2025 -
Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
07/07/2025 -
The National Lung Health Alliance Warns that Politicizing Immunization Risks Lives – Especially for Canadians with Lung Conditions
07/07/2025 -
CORRECTION – Dr. Anosh Ahmed Supports Trump’s Statement on Chicago, Citing Ongoing Public Safety and Policy Challenges
07/07/2025 -
Ipsen - Bilan semestriel - 30 juin 2025
07/07/2025 -
Ipsen - Half year statement - 2025 06 30
07/07/2025 -
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
07/07/2025 -
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
07/07/2025 -
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
07/07/2025 -
VitalHub Announces Acquisition of Novari Health Inc.
07/07/2025 -
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
07/07/2025 -
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
07/07/2025 -
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
07/07/2025 -
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
07/07/2025 -
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
07/07/2025
Pages